Home arrow Bladder Cancer arrow Colorectal Cancer Diagnosis Tuesday, 02 December 2008



 
Slick RSS
MedicineNet Cancer General
MedicineNet Cancer General
MedicineNet Logo
MedicineNet Depression General
MedicineNet Depression General
MedicineNet Logo
Cancer / Oncology News From Medical News Today
Latest Cancer / Oncology News From Medical News Today.
  • Marshall Edwards, Inc. Files IND Application For Triphendiol - Locally Advanced Or Metastatic Pancreatic And Bile Duct Cancers
    Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has filed an application with the United States Food and Drug Administration for an Investigative New Drug (IND) approval to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine.
  • Earlier Detection Of Cancer And Better Treatment For Survivors, UK
    Work is well underway to catch more cancer cases earlier and improve the longer term treatment for cancer survivors, National Cancer Director Professor Mike Richards said today. The first annual report setting out the Government's progress against the Cancer Reform Strategy, "Maintaining Momentum, Building for the Future", highlights the achievements made in the first year and identifies priorities for the year ahead.
  • Combining Targeted Therapy Drugs May Treat Previously Resistant Tumors
    A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches.
  • Study Unmasks How Ovarian Tumors Evade Immune System
    Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked. Ovarian cancer is considered to be one of the most aggressive malignancies, killing more than 70 percent of diagnosed women within five years, including an estimated 15,000 this year.
  • Merck Serono: European Commission Approves Erbitux For 1st-Line Use In Head And Neck Cancer
    Merck Serono, a division of Merck KGaA, announced today that it has received approval from the European Commission to extend the use of its targeted therapy Erbitux® (cetuximab) to include 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Erbitux was previously approved for use in combination with radiotherapy for locally advanced disease.